Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. provides an AI-powered software platform to non‑invasively diagnose and manage coronary artery disease using coronary CT angiography. As of December 31, 2025, its Heartflow Platform has been used in more than 600,000 patients and deployed at over 1,465 U.S. accounts.
The company’s flagship Heartflow FFRCT Analysis, which represented 98% of revenue as of December 31, 2025, estimates vessel-specific blood flow and lesion significance, while Heartflow Plaque Analysis quantifies and characterizes coronary plaque. A workflow tool, Heartflow RoadMap Analysis, is integrated into accounts, and Heartflow PCI Navigator is expected to launch in the second quarter of 2026.
Heartflow emphasizes extensive clinical validation, citing over 200 studies and large randomized trials like PRECISE and FORECAST, and benefits from strong guideline support and Category I CPT codes for FFRCT (75580) and Plaque Analysis (75577). Its growth strategy focuses on expanding account adoption, increasing utilization within existing sites, broadening Plaque Analysis coverage, and investing in additional clinical evidence and product innovation.
Heartflow, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Q4 revenue was $49.1 million, up 40% year-over-year, and full-year revenue reached $176.0 million, also up 40%, driven mainly by higher U.S. FFRCT volume.
Q4 gross margin improved to 79.5%, with full-year gross margin at 76.8%, reflecting AI-driven productivity gains. However, full-year operating expenses of $199.3 million (113% of revenue) led to a GAAP net loss of $116.8 million, or ($3.17) per share.
On a non-GAAP basis, full-year net loss narrowed to $59.9 million, and Adjusted EBITDA was ($44.7) million. Heartflow ended 2025 with $280.2 million in cash, cash equivalents and investments, providing a substantial liquidity cushion to support continued investment and growth initiatives.
HTFL insider sale filing. A Form 144 discloses an intended sale of $243,125.00 worth of Common Stock equal to 9,725 shares, reported through Fidelity Brokerage Services LLC on 03/18/2026. The filing also lists prior reported dispositions in the past three months: 22,562 shares on 02/10/2026 for $619,556.99 and 12,837 shares on 03/10/2026 for $290,886.42.
The filing notes a stock option exercise dated 06/25/2024 involving 9,725 shares with cash consideration. These entries are routine filings under transfer rules for reported insiders and disclose planned and recent transactions in company equity.
Heartflow, Inc. director Timothy C. Barabe exercised stock options and acquired 8,667 shares of common stock on March 11, 2026 at $2.22 per share. Following the transaction, he directly owns 179,521 common shares. The option grant continues to vest in monthly installments through July 1, 2027, subject to his continued service.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported mixed share activity. He sold 12,837 shares of common stock in an open-market transaction at $22.66 per share, executed under a pre-arranged Rule 10b5-1 trading plan.
Earlier, he acquired 2,631 shares at $16.15 per share as a grant under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). After these transactions, he directly holds 581,450 shares of Heartflow common stock.
HTFL provided a Form 144 notice reporting proposed and recent sales of common stock by an affiliate. The filing shows a proposed sale related to a 06/25/2024 stock option exercise for 12,837 shares and discloses that John C. M. Farquhar sold 22,562 common shares on 02/10/2026 for $619,556.99.
Heartflow, Inc. director Julie A. Cullivan reported an open-market sale of 9,122 shares of common stock at $25.00 per share on March 5, 2026. After this transaction, she held 27,291 shares directly. The sale was executed under a previously adopted Rule 10b5-1 trading plan dated September 12, 2025.
Heartflow, Inc. Schedule 13G/A lists Wellington entities as beneficial owners of common stock with 11,921,247 shares reported and 14.00% of the class. The filing identifies shared voting power and shared dispositive power figures and lists related Wellington subsidiaries and investment advisers. The filing is signed and dated 03/06/2026.
HTFL disclosed a Form 144 notice reporting proposed sales of common stock by affiliated holders.
The excerpt lists a sale by Julie A. Cullivan of 8,000 common shares on 02/05/2026 for $218,560. It also shows Fidelity Brokerage Services LLC with an entry of 9,122 tied to a 12/17/2024 stock option exercise paid in cash.
Heartflow, Inc. director Timothy C. Barabe reported exercising stock options for 2,497 shares of common stock on February 17, 2026. The options were converted into common shares at $8.33 per share, increasing his directly held stake to 170,854 common shares. This was an option exercise (code M), not an open-market purchase.